Dr. Reinhard Gabathuler reports

BIOMMUNE TECHNOLOGIES INC. GRANTS STOCK OPTIONS

Pursuant to the company's incentive stock option plan, bioMmune Technologies Inc. has granted incentive stock options to directors and officers of the company to purchase a total of 750,000 common shares in the capital stock of the company. The options are exercisable at a price of 31 cents per share (being the closing price of the company's stock on Friday, July 31, 2015) for a period of five years from the date of grant.

A total of 300,000 options are subject to vesting as to 75,000 options three months after the date of grant and 75,000 each quarter thereafter until fully vested (12 months following the date of grant). The remaining 450,000 options are subject to vesting as to 56,250 options three months after the date of grant and 56,250 each quarter thereafter until fully vested (24 months following the date of grant).

We seek Safe Harbor.